Home » Stocks » PTGX

Protagonist Therapeutics, Inc. (PTGX)

Stock Price: $21.30 USD -0.69 (-3.14%)
Updated December 3, 4:00 PM EST - Market closed

PTGX Stock Price Chart

Key Info

Market Cap 814.87M
Revenue (ttm) 25.70M
Net Income (ttm) -64.77M
Shares Out 37.39M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $21.30
Previous Close $21.99
Change ($) -0.69
Change (%) -3.14%
Day's Open 21.68
Day's Range 21.04 - 22.86
Day's Volume 235,884
52-Week Range 5.40 - 24.16

PTGX Stock News

PRNewsWire - 2 months ago

NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate...

PRNewsWire - 2 months ago

NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

PRNewsWire - 2 months ago

NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

PRNewsWire - 3 months ago

NEWARK, Calif., Sept. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

PRNewsWire - 3 months ago

NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Zacks Investment Research - 3 months ago

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 4 months ago

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 4 months ago

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Other stocks mentioned: BMY, KDMN
Seeking Alpha - 5 months ago

Why Protagonist Should Be On Your Radar After Latest Trial Update

Zacks Investment Research - 5 months ago

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromato...

PRNewsWire - 5 months ago

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

PRNewsWire - 5 months ago

NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate ...

Seeking Alpha - 5 months ago

Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning

PRNewsWire - 6 months ago

NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment...

PRNewsWire - 6 months ago

NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at tw...

Seeking Alpha - 6 months ago

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 6 months ago

Here's what's behind their impressive market performances.

Other stocks mentioned: MGNX, STML
Zacks Investment Research - 6 months ago

Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.

Zacks Investment Research - 6 months ago

Why is Protagonist Therapeutics (PTGX) Soaring 90% Today?

zacks.com zacks.com/ultimate

The Motley Fool - 6 months ago

The company is set to start a pivotal study for one of its lead pipeline candidates.

Seeking Alpha - 8 months ago

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead f...

Zacks Investment Research - 9 months ago

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

The Motley Fool - 11 months ago

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Other stocks mentioned: AGN, ALEC, AMRN, ATNX, BHVN, CARA, GBT, ITCI, NVS, PBYI, PTI, RCKT
Seeking Alpha - 1 year ago

Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -337.04% and -176.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead f...

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for...

Zacks Investment Research - 1 year ago

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About PTGX

Protagonist Therapeutics, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta... [Read more...]

Industry
Biotechnology
IPO Date
Aug 11, 2016
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
PTGX
Full Company Profile

Financial Performance

In 2019, PTGX's revenue was $231,000, a decrease of -99.25% compared to the previous year's $30.93 million. Losses were -$77.19 million, 98.3% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for PTGX is 31.75, which is an increase of 49.06% from the latest price.

Price Target
$31.75
(49.06% upside)